RxDoctor Payments DataLook up a doctor →

Bhairavi Sheshadri, MD

Endocrinology, Diabetes & Metabolism · Raleigh, NCNPI 1255745188

Payments from drug & device makers

$27,634in general payments, 2019–2025

Across 896 payments — averaging $30.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$8K
  • Medtronic$3K
  • Corcept Therapeutics$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Abbott$1K
  • plus $9K from 52 others

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cequr Corporation5$8,242
Medtronic(2 entities)34$2,861
Corcept Therapeutics45$2,752
Novo Nordisk144$2,002
Lilly USA, LLC132$1,877
Abbott71$1,397
Amgen(2 entities)37$808
AbbVie35$567
Radius Health, Inc.36$546
Mannkind Corporation44$538
IBSA Pharma Inc.30$513
Antares Pharma, Inc.20$443
Sanofi-aventis U.S. LLC22$402
Dexcom, Inc.16$390
Xeris Pharmaceuticals, Inc.19$383
Bayer21$380
Boehringer Ingelheim18$361
Esperion Therapeutics, Inc.21$301
AstraZeneca20$294
Insulet Corporation8$294
Sequel Med Tech, LLC4$271
Almatica Pharma LLC15$178
Ascendis Pharma Endocrinology Inc8$142
Novartis7$127
Amarin Pharma, Inc.8$118
Recordati_rare_diseases_inc.6$114
Neurocrine Biosciences, Inc.4$94
BETA Bionics, Inc.3$94
Amneal Pharmaceuticals LLC5$78
Tolmar, Inc.3$76
Halozyme Inc4$76
Rhythm Pharmaceuticals, Inc.4$74
Merck5$73
Vivus LLC4$66
Lifescan, Inc.3$60
Nevro Corp.3$57
Astellas Pharma US Inc3$51
Aimmune Therapeutics, Inc.2$51
Azurity Pharmaceuticals, Inc.3$49
Kowa Pharmaceuticals America, Inc.3$43
Kyowa Kirin, Inc.2$41
Boston Scientific1$40
Madrigal Pharmaceuticals1$40
Nestle Healthcare Nutrition Inc.2$38
Clarus Therapeutics Inc.2$24
Arbor Pharmaceuticals, Inc.1$21
Regeneron Healthcare Solutions, Inc.1$20
Soleno Therapeutics, Inc.1$20
Embecta Corp.1$20
Amphastar Pharmaceuticals, Inc.1$19
Amryt Pharma Holdings Ltd1$16
Pfizer1$16
Verity Pharmaceuticals Inc.1$15
Acella Pharmaceuticals, LLC1$14
Currax Pharmaceuticals LLC1$14
Ipsen Biopharmaceuticals, Inc1$13
EUSA Pharma (US) LLC1$13
Takeda Pharmaceuticals U.S.A., Inc.1$12

How this compares

$27,634 in reported general payments places this provider in the 75th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina →

Medicare billing

Part B allowed, 2024
$78,136
Medicare patients
231
Services billed
735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Raleigh

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →